Evidence map›Paper›PMID 36289632›Full record

ArticleBiomedicines2022

Correlation between Macular Neovascularization (MNV) Type and Druse Type in Neovascular Age-Related Macular Degeneration (AMD) Based on the CONAN Classification.

Daniel Rudolf Muth, Mario Damiano Toro, Anahita Bajka, Kamil Jonak, Roman Rieder, Myrtha Magdalena Kohler, Jeanne Martine Gunzinger, Eric H Souied, Michael Engelbert, K Bailey Freund and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Cuticular drusen in Asian neovascular age-related macular degeneration: Clinical features and polypoidal choroidal vasculopathy association.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Early prediction of macular neovascularization phenotypes and prognostic evolution.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 5 countries.

Daniel Rudolf MuthDepartment of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland.ORCID 0000-0003-3670-976X
Mario Damiano ToroDepartment of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland.ORCID 0000-0001-7152-2613
Anahita BajkaDepartment of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland.
Kamil JonakDepartment of Biomedical Engineering, Lublin University of Technology, 20-618 Lublin, Poland.ORCID 0000-0002-9975-1458
Roman RiederDepartment of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland.
Myrtha Magdalena KohlerDepartment of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland.
Jeanne Martine GunzingerDepartment of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland.ORCID 0000-0001-9005-347X
Eric H SouiedDepartment of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris Est Creteil, 94000 Creteil, France.
Michael EngelbertVitreous Retina Macula Consultants of New York, New York, NY 10022, USA.
K Bailey FreundVitreous Retina Macula Consultants of New York, New York, NY 10022, USA.
Sandrine Anne ZweifelDepartment of Ophthalmology, University Hospital Zurich (USZ), University of Zurich (UZH), 8091 Zurich, Switzerland.ORCID 0000-0001-7431-1774
University of Zurich · CHMedical University of Lublin · PLVitreous Retina Macula Consultants of New York · USUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate associations and predictive factors between macular neovascularization (MNV) lesion variants and drusen types in patients with treatment-naïve neovascular age-related macular degeneration (AMD). Methods: Multimodal imaging was retrospectively reviewed for druse type (soft drusen, subretinal drusenoid deposits (SDDs) or mixed) and MNV type (MNV 1, MNV 2, MNV 1/2 or MNV 3). The Consensus on Neovascular AMD Nomenclature (CONAN) classification was used for characterizing MNV at baseline. Results: One eye of each eligible patient was included (n = 191). Patients with predominant SDDs had an increased adjusted odds ratio (aOR) for MNV 2 (23.4453, p = 0.0025) and any type of MNV 3 (8.7374, p < 0.0001). Patients with MNV 1/2 had an aOR for predominant SDDs (0.3284, p = 0.0084). Patients with MNV1 showed an aOR for SDDs (0.0357, p < 0.0001). Eyes with SDDs only without other drusen types showed an aOR for MNV 2 (9.2945, p < 0.0001). Conclusions: SDDs represent a common phenotypic characteristic in AMD eyes with treatment-naïve MNV. The aOR for eyes with predominant SDDs to develop MNV 2 and MNV 3 was much higher, possibly due to their location in the subretinal space. The predominant druse type may help to predict which type of MNV will develop during the course of AMD.

Indexed as

age-related macular degenerationAMDCNVmacular neovascularizationMNVOCTreticular pseudodrusenSDDsspectral domain optical coherence tomographysubretinal drusenoid deposits

Identifiers

PMID36289632
PMCPMC9598373
OpenAlexW4296849288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.